Leslie Tari - 01 Jul 2021 Form 3 Insider Report for Cidara Therapeutics, Inc. (CDTX)

Role
Chief Scientific Officer
Signature
/s/ Leslie Tari
Issuer symbol
CDTX
Transactions as of
01 Jul 2021
Net transactions value
$0
Form type
3
Filing time
06 Jul 2021, 16:29:32 UTC
Next filing
30 Jul 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CDTX Common Stock 2,551 01 Jul 2021 Direct
holding CDTX Common Stock 13,298 01 Jul 2021 By spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CDTX Stock Option (right to buy) 01 Jul 2021 Common Stock 30,708 $2.29 Direct F1
holding CDTX Stock Option (right to buy) 01 Jul 2021 Common Stock 49,739 $2.45 Direct F2
holding CDTX Stock Option (right to buy) 01 Jul 2021 Common Stock 79,221 $2.45 Direct F1
holding CDTX Stock Option (right to buy) 01 Jul 2021 Common Stock 85,000 $1.98 Direct F3
holding CDTX Stock Option (right to buy) 01 Jul 2021 Common Stock 120,000 $2.55 Direct F4
holding CDTX Restricted Stock Unit 01 Jul 2021 Common Stock 3,675 Direct F5, F6
holding CDTX Stock Option (right to buy) 01 Jul 2021 Common Stock 918 $2.45 By spouse F1
holding CDTX Stock Option (right to buy) 01 Jul 2021 Common Stock 3,927 $2.45 By spouse F1
holding CDTX Stock Option (right to buy) 01 Jul 2021 Common Stock 521 $1.98 By spouse F1
holding CDTX Stock Option (right to buy) 01 Jul 2021 Common Stock 104 $2.55 By spouse F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares are fully vested
F2 One-third (1/3) of the shares subject to the option vested on December 18, 2020 and the remainder vests and becomes exercisable in a series of twenty-four (24) successive equal monthly installments thereafter until fully vested on December 18, 2022.
F3 The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 19, 2020.
F4 The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 17, 2021.
F5 The shares shall vest upon the achievement of various clinical and corporate milestones.
F6 Restricted stock units convert into common stock on a one-for-one basis.